Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in syncytiotrophoblasts | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 1,968 | 0.79 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7797
Sealed predictions
- CEBPA in dopamine neurons, braakn/a → n/areceipt 7805
- CEBPA in microglia, braak-0.19 (p 0.619) → -0.46 (p 0.209)receipt 7804
Swarm cases
receipt 7805: CEBPA in dopamine neurons, braak
- cell type
- CEBPA is not measured in dopamine neurons; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CEBPA in dopamine neurons.
case closed: nothing better to follow up.
receipt 7804: CEBPA in microglia, braak
- power
- full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.23 (p 0.360, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.27 (p 0.273, n 18). could be the mix.
- skeptic
- leave-one-out range -0.32 to -0.12, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CEBPA in microglia.
case closed: nothing better to follow up.
Receipts
loading the receipts